Edwards Lifesciences Corp
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
EW$104.01-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net income | $923.5 | $978.2 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 128.5 | 113.9 |
| Non-cash operating lease cost | 19.8 | 19.3 |
| Stock-based compensation (Note 10) | 133.6 | 118.9 |
| Impairment of intangible and long-lived assets (Note 2) | 220.2 | 40.0 |
| Change in fair value of contingent consideration liabilities | — | (12.5) |
| (Gain) loss on investments, net | (31.6) | 6.4 |
| Deferred income taxes | 130.1 | (63.2) |
| Gain on remeasurement of previously held interest upon business combinations (Note 7) | (85.1) | — |
| Loss on impairment (Note 6) | 163.6 | 47.1 |
| Other | (1.3) | (4.1) |
| Changes in operating assets and liabilities: | ||
| Accounts and other receivables, net | (148.0) | (55.4) |
| Inventories | (49.7) | 39.7 |
| Accounts payable and accrued liabilities | (156.2) | 226.4 |
| Income taxes | 97.7 | (199.4) |
| Prepaid expenses and other current assets | (2.0) | (17.5) |
| Intellectual property agreement accrual | (50.0) | (61.7) |
| Other | (27.1) | (31.8) |
| Net cash provided by operating activities | 1,266.0 | 1,144.3 |
| Cash flows from investing activities | ||
| Capital expenditures | (195.4) | (162.8) |
| Investments in unconsolidated affiliates | (13.7) | (49.8) |
| Purchases of held-to-maturity investments (Note 5) | (39.1) | (43.2) |
| Proceeds from held-to-maturity investments (Note 5) | 39.2 | 54.2 |
| Purchases of available-for-sale investments (Note 5) | (1,855.5) | (2,265.2) |
| Proceeds from available-for-sale investments (Note 5) | 1,624.4 | 2,109.4 |
| Payment for working capital adjustment for sale of product group (Note 4) | — | (36.3) |
| Business combinations, net of cash (Note 7) | (33.7) | — |
| Payment for acquisition options | (4.0) | (19.6) |
| Issuances of notes receivable | (55.2) | (93.4) |
| Other | (9.4) | (7.9) |
| Net cash used in investing activities | (542.4) | (514.6) |
| Cash flows from financing activities | ||
| Purchases of treasury stock | (714.0) | (852.8) |
| Purchase of remaining noncontrolling interest in subsidiary (Note 6) | — | (233.7) |
| Proceeds from stock plans | 159.2 | 141.8 |
| Other | 2.5 | (0.7) |
| Net cash used in financing activities | (552.3) | (945.4) |
| Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash | 1.6 | (48.3) |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 172.9 | (364.0) |
| Cash, cash equivalents, and restricted cash at beginning of period | 2,939.5 | 3,058.8 |
| Cash, cash equivalents, and restricted cash at end of period (Note 2) | $3,112.4 | $2,694.8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.